Benjamin (Ben) Prosser is an Associate Professor of Physiology at the University of Pennsylvania Perelman School of Medicine. He earned his Ph.D. in Molecular Medicine under Dr. Martin Schneider at the University of Maryland School of Medicine in 2009, and then completed his post-doc in Molecular Cardiology under Dr. Jon Lederer at Maryland in 2013.
Dr Davidson is the Director of Translational Research at ENDD, the Chief Scientific Strategy Officer and Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and the Arthur V. Meigs endowed Chair in Pediatrics at the Children’s Hospital of Philadelphia. She is also Professor of Pathology and Laboratory Medicine and Professor of Genetics at the Perelman School of Medicine,
Dr Helbig is the Director of Clinical Research at ENDD, an attending Pediatric Neurologist in the Division of Neurology and the Director of Genomic Science at Children’s Hospital of Philadelphia (CHOP), and an Assistant Professor of Neurology at the Perelman School of Medicine, University of Pennsylvania.
Dr Helbig co-headed the EuroEPINOMICS-RES Consortium,
Michael Boland is a cellular/molecular biologist with expertise in human stem cell technology, transcriptomics, epigenetics, developmental neurobiology, disease model-development, gene-targeted therapy development, and drug discovery.
He obtained a PhD in Biochemistry and Molecular Biology at the University of Nebraska Medical Center (Omaha, NE) where he identified and characterized a novel link between DNA methylation and DNA repair in embryonic stem cells.
Dr. French manages the human stem cell model development of ENDD. She is also Director of the Human Pluripotent Stem Cell Core at The Children’s Hospital of Philadelphia (CHOP) and a Research Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, University of Pennsylvania.
Dr.
The Heller Lab research program is focused on elucidating the causal mechanisms by which epigenetic reprogramming contributes to neuropsychiatric and neurodevelopmental disease. The Heller lab applies targeted epigenetic editing to determine the direct causal relevance of histone modifications to transcription, alternative splicing, and behavior. This approach will be applied to SynGAP1,